0001764013-23-000087.txt : 20230808 0001764013-23-000087.hdr.sgml : 20230808 20230808164448 ACCESSION NUMBER: 0001764013-23-000087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230807 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Salzmann Peter CENTRAL INDEX KEY: 0001796309 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38906 FILM NUMBER: 231152145 MAIL ADDRESS: STREET 1: 320 W 37TH STREET, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 4 1 wf-form4_169152738079375.xml FORM 4 X0508 4 2023-08-07 0 0001764013 Immunovant, Inc. IMVT 0001796309 Salzmann Peter C/O IMMUNOVANT, INC. 320 W 37TH STREET, 6TH FLOOR NEW YORK NY 10018 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-08-07 4 S 0 101339 21.73 D 1129797 D On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. Settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of 178,316 of the RSUs and do not represent a discretionary sale by the holder. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.26 - $22.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. /s/ Eva Renee Barnett, attorney-in-fact for Peter Salzmann 2023-08-08